Business
Editas Medicine Announces Second Quarter 2020 Results and Update
Regained full control of ocular medicines under new agreement with AbbVie BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of
About this update from Editas Medicine, Inc.
[{"type":"text","content":"Regained full control of ocular medicines under new agreement with AbbVie \n BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of 2020 Plan to file IND for EDIT-301 for sickle cell disease by end of 2020 Strengthened balance sheet through equity offering raising $216 million in gross proceeds Cash, cash equivalents, and marketable securities of $599 million as of June 30, 2020 CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the second quarter of 2020. “I am extremely proud of our recent progress, as we remain on track with previously shared guidance despite the unpredictable challenges presented by COVID-19,” said Cynthia Collins, Chief Executive Officer of Editas Medicine. “Our lead program evaluating EDIT-101 for the treatment of Leber congenital amaurosis 10 has continued to advance with dosing resuming in the Phase 1/2 BRILLIANCE trial, further solidifying Editas as the leader in the field of in vivo gene editing. Substantial progress has also been made toward an IND filing for EDIT-301 this year, with recent data presented at EHA providing preclinical proof-of-concept for this potentially best-in-class cell medicine for sickle cell disease.” Ms. Collins continued, “Alongside the clinical and scientific advances made last quarter, we also executed on several corporate milestones to better position the Company as we expand our clinical-stage pipeline. To ensure the efficient advancement of our pioneering gene editing medicines, we strengthened our balance sheet with the closing of a common stock offering resulting in gross proceeds of approximately $216 million. Importantly, we also secured dedicated cGMP-compliant manufacturing space to facilitate the completion of IND-enabling studies and early stage clinical manufacturing for our engineered cell medicines including EDIT-301 for sickle cell disease and EDIT-201, an allogeneic NK cell medicine for solid tumors.” Recent Achievements and Outlook In Vivo CRISPR Medicines Ocular Medicines Regained full control of ocular medicinesEditas Medicine (Company) has terminated its 2017 agreement with Allergan, now part of AbbVie, and entered a new agreement with AbbVie that returns development and commercialization rights fo...